PL EN


Preferences help
enabled [disable] Abstract
Number of results
2018 | 75 | 5 | 1069-1082
Article title

ADVANCES AND LIMITATIONS IN PHARMACOTHERAPY OF EPILEPSY

Authors
Content
Title variants
Languages of publication
EN
Abstracts
EN
Epilepsy is a chronic neurologic disorder that affects about 0.7% of the population. Patients with epilepsy suffer from recurrent seizures, which can be focal or generalized in nature. The third-generation of anticonvulsant drugs includes lacosamide, rufinamide, vigabatrin, retigabine, perampanel, eslicarbazepine acetate, brivaracetam and stiripentol. Other compounds, such as ganaxolone, cannabidiol, selurampanel, and everolimus among others, with different mechanisms of action are currently in clinical development. Furthermore, numerous compounds or classes of compounds are investigated in preclinical studies. Nevertheless, about 30% of epilepsy patients suffer from uncontrolled seizures despite pharmacotherapy, including the third-generation of anticonvulsant drugs. Additionally, the occurrence of adverse drug effects is responsible for poor compliance as well as discontinuation of the therapy, in up to 25% of patients before having reached the effective dose amount. Neuropsychiatric undesirable effects, include depression, aggression, irritable mood, anxiety, mood instability, paranoid ideation, delusions, hallucinations. Moreover, suicidal ideation and behaviour have been reported in patients treated with anticonvulsant drugs.
Year
Volume
75
Issue
5
Pages
1069-1082
Physical description
Dates
published
2018-10-31
Contributors
author
References
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.doi-10_32383_appdr_83591
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.